Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

SM04690 Promising for Knee OA

Michele B. Kaufman, PharmD, BCGP  |  March 27, 2019

SM04690, an intra-articular injection for knee OA, will soon enter phase 3 trials to assess its effects on pain, joint function and disease…

Filed under:Drug Updates Tagged with:disease-modifying osteoarthritis drug (DMOAD)joint injectionkneeKnee Osteoarthritis (OA)OsteoarthritisSM04690

FDA Approves Guselkumab Injector

Michele B. Kaufman, PharmD, BCGP  |  March 20, 2019

The FDA has approved a single-press, self-injection device for a 100-mg dose of guselkumab for adults with moderate to severe plaque psoriasis…

Filed under:Biologics/DMARDsDrug Updates

Osteoporosis Experts Discuss Bisphosphonates, Chronic Kidney Disease

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—The osteoporosis session at the 2018 ACR/ARHP Annual Meeting opened with a discussion by Kenneth Saag, MD, MSc, professor of medicine at the University of Alabama, Birmingham, in which he highlighted adverse events associated with osteoporosis medications. Dr. Saag began his presentation by emphasizing that, above all, the audience should keep in mind that the…

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:2018 ACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)bisphosphonateschronic kidney diseaseOsteoporosis

The Latest on Vaccinations, Leprosy & Lyme Disease

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—Keith Winthrop, MD, MPH, professor of public health and preventive medicine at the Oregon Health & Science University School of Medicine, Portland, Ore., began the vaccination session at the 2018 ACR/ARHP Annual Meeting with a review of vaccination timing and targets. He presented a clinically relevant snapshot of the vaccines rheumatologists should consider and emphasized…

Filed under:ConditionsMeeting Reports Tagged with:2018 ACR/ARHP Annual MeetingleprosyLyme Diseasevaccination

Disease Mimicry: Genetic Diseases Can Produce Rheumatic Symptoms

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—The 2018 ACR/ARHP Annual Meeting session on genetic mimics of rheumatic disease began with a description of a patient who presented with the symptoms of childhood-onset lupus but instead had a well-defined genetic disease: lysinuric protein intolerance (LPI). Lindsay Burrage, MD, PhD, assistant professor of molecular and human genetics at Baylor College of Medicine, Houston,…

Filed under:ConditionsMeeting Reports Tagged with:2018 ACR/ARHP Annual MeetingFabry diseasegenetic diseaselysinuric protein intolerancemimics

Treating Lupus: Strategies, Treat to Target & Biologics

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—David A. Isenberg, MD, academic director of rheumatology, University College London, presented the ACR Systemic Lupus Erythematosus (SLE) State-of-the-Art Symposium at the 2018 ACR/ARHP Annual Meeting. Dr. Isenberg began by noting lupus is now widely covered in the news, but singer Selena Gomez has probably done the most to increase awareness of the disease; her…

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:2018 ACR/ARHP Annual MeetingabataceptbelimumabTreat-to-Target

Pediatric Uveitis in the Biologic Age: Risk Factors, Treatment & Outcomes

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—The session on the topic of pediatric uveitis at the 2018 ACR/ARHP Annual Meeting began with a presentation by Debra A. Goldstein, MD, professor of ophthalmology and director of the Uveitis Service at the Feinberg School of Medicine, Northwestern University, Chicago. To a room packed with rheumatologists, she explained, “Most of what I am going…

Filed under:ConditionsMeeting Reports Tagged with:2018 ACR/ARHP Annual MeetingUveitis

Living Well with Scleroderma

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—Can non-drug interventions improve the lives of patients with scleroderma? Janet L. Poole, PhD, OTR/L, professor and director of the Occupational Therapy Graduate Program of the School of Medicine, University of New Mexico, Albuquerque, addressed this question when she presented the ARHP Distinguished Lecture at the 2018 ACR/ARHP Annual Meeting. She discussed the challenges faced…

Filed under:ConditionsMeeting ReportsSystemic Sclerosis Tagged with:2018 ACR/ARHP Annual Meetingnon-pharmaceutical therapies

Destructive Arthritis: From Prevention to Progression to Remission

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—Josef S. Smolen, MD, professor of internal medicine and chair of the Department of Rheumatology, Vienna General Hospital, Austria, presented the prestigious Paul Klemperer, MD, Memorial Lecture at the 2018 ACR/ARHP Annual Meeting. Dr. Smolen, whose work is frequently cited, created the treat-to-target strategy for rheumatoid arthritis (RA). Dr. Smolen began by noting a simple…

Filed under:ConditionsMeeting ReportsRheumatoid Arthritis Tagged with:2018 ACR/ARHP Annual MeetingTreat-to-Target

State-of-the-Art Approaches to Rheumatic Disease Diagnosis, Management & Treatment

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—Held during the 2018 ACR/ARHP Annual Meeting, the ACR Review Course covered a wide range of topics for rheumatologists—from advances in pain and rheumatic disease management to the intersection of rheumatology and neurology. Session speakers shared insights, as well as state-of-the-art approaches to diagnosis, management and treatment. Inflammatory Myopathies Julie J. Paik, MD, MHS, assistant…

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone DisordersPain SyndromesSystemic Lupus Erythematosus Tagged with:2018 ACR/ARHP Annual MeetingFibromyalgiaOsteoporosisperioperative period

  • « Previous Page
  • 1
  • …
  • 95
  • 96
  • 97
  • 98
  • 99
  • …
  • 243
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences